

# Phospho-EGFR (Tyr1092) Rabbit Monoclonal Antibody

# Catalog #: EAB21439

Host/Isotype	Clonality	Applications	MW (kDa)	Reactivity
Rabbit IgG	Monoclonal	WB, IHC-P, IF/ICC	134	Human, Mouse

#### **Applications Dilutions**

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

WB(Western Blotting)	1:500-2000
IHC-P(Immunohistochemistry-Paraffin)	1:50-200
IF/ICC(Immunofluorescence/Immunocytochemistry)	1:50-200

#### **Product Information**

Conjugate	Unconjugate
Specificity	Phospho-EGFR (Tyr1092) Rabbit Monoclonal Antibody detects endogenous levels of EGFR only when phosphorylated at Tyr1092.
Purification	Affinity purification
Concentration	1mg/ml
Format	Liquid
Formulation	In PBS, pH 7.4, Containing 0.02% sodium azide, 0.5% BSA and 50% Glycerol
Shipping	Gel Pack
Storage	Store at -20°C least 1 year from the date of shipment. Avoid repeated freeze/thaw cycles. Aliquots may be stored at +4°C for 1-2 weeks
UniProt ID	P00533
Entrez-Gene Id	<u>1956</u>

### **Product Description**

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Exons in the EGFR gene product are frequently either deleted or duplicated to produce deletion mutants (DM) or tandem duplication mutants (TDM), respectively, which are detected at various molecular weights. EGFR binds several ligands, including epidermal growth factor (EGF), transforming growth factor  $\alpha$  (TGF $\alpha$ ), Amphiregulin and heparin binding-EGF (HB-EGF). Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target.

For Reserch Use Only. Not For Use In Diagnostic Procedures